# Amgen

**Canonical:** https://apis.io/providers/amgen/  
**Website:** https://www.amgen.com  
**APIs profiled:** 1

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. As a pioneer in biotechnology since 1980, Amgen uses living cells to make biologic medicines addressing cardiovascular metabolic conditions, oncology, inflammation, rare diseases, and bone health, operating in approximately 100 countries worldwide.

## Kin Score — 16.9 / 100 (emerging)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 16.9).

| Facet | Score |
|---|---|
| Discoverability | 68.5 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 7.9 |
| Developer Ergonomics | 11.9 |
| Commercial Clarity | 34.2 |
| Access Clarity | 34.2 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 3.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | documented |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## APIs (1)

- **Amgen Website** — Amgen discovers, develops, manufactures, and delivers innovative biologic medicines for patients with serious illnesses. The company does not currently publish a public develope...

## Security (1)

- **Amgen Domain Security** — TLSv1.3 · DMARC

## Plans (1)

- **Amgen Plans Pricing**

## Use cases (6)

- **Cancer Treatment** — Providing oncology medicines for patients with solid tumors and blood cancers through innovative biologic and targeted therapies.
- **Heart Disease Prevention** — Reducing cardiovascular risk with medicines targeting LDL cholesterol, Lp(a), and other cardiovascular risk factors.
- **Inflammatory Disease Management** — Managing chronic inflammatory conditions with targeted biologic therapies for patients with severe unmet medical needs.
- **Rare Disease Treatment** — Delivering life-changing therapies to patients with rare and ultra-rare diseases where few or no other treatments exist.
- **Biosimilar Access** — Improving patient access to biologic therapies through high-quality, lower-cost biosimilar medicines.
- **Weight Management** — Addressing obesity and obesity-related conditions with novel medicines targeting metabolic pathways.

## Tags

Biotechnology, Biopharmaceutical, Oncology, inflammation, Cardiovascular, Rare Disease, Biosimilars, Life Sciences, Fortune 500

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/amgen/). Scores are computed from the provider's own public artifacts under a published rubric.